Suggested remit: To appraise the clinical and cost effectiveness of tezepelumab within its marketing authorisation for treating severe chronic rhinosinusitis with nasal polyps.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6379
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators:
- 12 September 2025 - 10 October 2025
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 September 2025 | In progress. Scoping commenced. |
| 12 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 12 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual